Denise A. Yardley, MD

Denise A. Yardley, MD, senior investigator, Sarah Cannon Research Institute, on the treatment of patients with breast cancer with bone health issues.

Read about detecting cancer-induced bone disease > >

Articles

The Treatment of Patients With Bone Health Issues

Denise A. Yardley, MD, from Sarah Cannon Research Institute, discusses toxicities associated with treatment with PI3K inhibitors for breast cancer.

Toxicities Associated With PI3K Inhibitors

Denise A. Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the role of Afinitor (everolimus) in breast cancer and the BOLERO trials.

The next steps in testing the role of everolimus in breast cancer include extending the benefit seen in advanced patients with metastatic disease to an early disease setting. Yardley says that trials are launching to measure the role of everolimus in improving cure rates in patients with early-stage postmenopausal hormone receptor-positive disease.

While the oncology community is awaiting results from the BOLERO-1 trial, the BOLERO-2 and BOLERO-3 trials demonstrated significant benefit. Results from the BOLERO-2 trial showed a doubling in progression-free survival in postmenopausal patients who were hormone receptor-positive. Yardley says that the PI3K/AKT/mTOR pathway, which was central in the BOLERO-2 trial, could play a role in HER2-positive patients. Data from the BOLERO-3 trial showed an extended control of disease when everolimus was added to chemotherapy and trastuzumab for the treatment of patients with HER2-positive disease.

Everolimus should be looked at to extend the benefit seen in advanced patients with metastatic disease to an earlier disease setting

Trials are launching to measure the role of everolimus in improving cure rates in patients with early-stage postmenopausal HR+ disease

BOLERO-2 showed a doubling in PFS for patients with HR+ postmenopausal patients

The PI3K/AKT/mTOR pathway could play a role in HER2+ patients

The oncology community is eagerly awing results from the BOLERO-1 trial

Results from BOLERO-3 demonstrated that everolimus plus chemotherapy and trastuzumab extended control of disease

Videos

The Role of Everolimus in Breast Cancer and the BOLERO Trials

Denise A. Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, discusses an expanded access study of T-DM1 in previously treated HER2-positive metastatic breast cancer.

This analysis was not as stringent as a conventional clinical trial, Yardley says, and aimed to evaluate patients treated with T-DM1 in the community setting. In this trial, patients received a median of 8 prior therapies and were able to receive T-DM1 before its FDA approval.

The time from initial metastatic diagnosis to receiving T-DM1 in this trial was a mean of 42 months, Yardley says, which is astounding and highlights the benefit of HER2-targeted therapies. Among patients who remained on T-DM1 for over a year, median time from diagnosis to T-DM1 was 60 months. This as well reinforces the advancements of HER2-targeted therapies, Yardley says.

This trial looked at T-DM1 in the community setting of patients

The patient population received a median of 8 prior therapies for HER2+ metastatic disease

Safety profile and activity were similar to previous conventional clinical trials

Denise A. Yardley, MD | Authors

Articles

The Treatment of Patients With Bone Health Issues

Toxicities Associated With PI3K Inhibitors

The Role of Everolimus in Breast Cancer and the BOLERO Trials

An Expanded Access Study of T-DM1 in Previously Treated HER2-Positive Metastatic Breast Cancer